Pleuropéricardite sévère associée à un traitement par bromocriptine au long cours, revue de la littérature à propos d’un cas

Ciubotaru, V.; Poinsignon, Yves; Brunet-Bourgin, F.; Mestassi, M.; Rosenbaum, Dieter

doi:10.1016/j.revmed.2004.01.004

Cited by 8 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most of them had pleural thickening and pleural effusions [4–7], usually bilateral or on the right side, but some also had pulmonary interstitial infiltrates [8] and restrictive ventilatory changes [6]. Constrictive pericarditis, in some cases with associated pleural effusion, has also been described [9–11]. …”

Section: Discussionmentioning

confidence: 99%

Investigating a Case of Recurrent Pleural Effusion

Rodrigues

Neves

Ferreira

et al. 2011

Case Reports in Pulmonology

View full text Add to dashboard Cite

We describe the case of a patient with long-standing Parkinson's disease and recurrent bilateral pleural effusions. The pleural fluid was an exudate, rich in normal lymphocytes, and the echocardiogram, chest computerized axial tomography, and immunological, microbiological and cytological studies were negative. The patient had been taking bromocriptine, which can be related to chronic pleural effusions. Using Pubmed, we found about 40 cases of pleuropulmonary changes or constrictive pericarditis that were related to bromocriptine. We decided to suspend this drug, with resolution of the pleural effusion and respiratory complaints for more than a year now. We discuss possible underlining mechanisms for this and emphasize the importance of collecting the past medical history and medication and of considering possible iatrogenic effects.

show abstract

Section: Discussionmentioning

confidence: 99%

Investigating a Case of Recurrent Pleural Effusion

Rodrigues

Neves

Ferreira

et al. 2011

Case Reports in Pulmonology

View full text Add to dashboard Cite

show abstract

“…Our patient presented all these features. Cases of constrictive pericarditis [11] and cardiac valve regurgitation [3] have also been reported. The time between the initiation of treatment and appearance of symptoms ranges between 5 and 48 months (Table 2 ); in our case, the clinical symptoms appeared after 3 years of treatment…”

Section: Discussionmentioning

confidence: 99%

Pleuropulmonary Toxicity of Another Anti-Parkinson`s Drug: Cabergoline

Belmonte¹,

Fábregues²,

Marti³

et al. 2009

TORMJ

View full text Add to dashboard Cite

Many drugs may cause toxic injury to the lungs and the pleura. Cabergoline is an ergoline derivative which has been used in Spain for seven years to control symptoms of Parkinson’s disease. We report a patient with dyspnea, bilateral pleural effusion and distal swelling. After a series of complementary tests (blood analysis, chest CT, echocardiogram, pleural tap, pleural biopsy), etiological screening ruled out infection, malignancy or inflammation. Given the patient’s history of three years’ treatment with cabergoline, the drug was considered a possible cause and was progressively withdrawn. The patient’s clinical condition improved and radiological images were disease-free. Using Karch and Lasagna’s classical criteria, we defined a relationship of “probable causality” between the drug and the adverse effects reported.

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2004

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

show abstract

Pleuropéricardite sévère associée à un traitement par bromocriptine au long cours, revue de la littérature à propos d’un cas

Cited by 8 publications

References 17 publications

Investigating a Case of Recurrent Pleural Effusion

Investigating a Case of Recurrent Pleural Effusion

Pleuropulmonary Toxicity of Another Anti-Parkinson`s Drug: Cabergoline

Current awareness: Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About